Halozyme Therapeutics Inc. (HALO)
NASDAQ
Closed
Oct 8, 2026
Day's Range
107.4152 wk Range
61.23Overview - HALO - Halozyme Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
14.41B
P/E (Trailing)
‪32.85‬
P/E (Forward)
‪10.56‬
PEG Ratio
‪0.74‬
Price / Sales (TTM)
‪7.66‬
Price / Book
‪89.25‬
EV / EBITDA
‪13.71‬
Profitability
Gross Margin
‪83.54%‬
Profit Margin
‪24.85%‬
Operating Margin
‪59.80%‬
Return on Assets
‪25.49%‬
Return on Equity
‪173.67%‬
Ownership
Shares Outstanding
114.04M
Float
112.18M
Short % of Shares Outstanding
‪17.50%‬
Held by Insiders
‪1.08%‬
Held by Institutions
‪113.09%‬
Price stats
Beta
‪0.87‬
50-Day Avg
‪105.10‬
200-Day Avg
‪79.21‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
9 analysts
Average price target
‪$ 99.56‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - HALO - Halozyme Therapeutics Inc.
Peers - HALO - Halozyme Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- HALONASDAQHalozyme Therapeutics Inc.12.13BMarket Cap+35.50%52-week change32.38P/E (Trailing)‪24.85%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - HALO - Halozyme Therapeutics Inc.
About
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
